The U.S. Food and Drug Administration (FDA) has conferred interchangeable status upon Biogen and Samsung Bioepis’s ranibizumab biosimilar, BYOOVIZ® (Ranibizumab-Nuna). The legal professionals would be cognizant of the fact that BYOOVIZ® has been deemed interchangeable with Genentech’s LUCENTIS for the treatment of several ophthalmic conditions, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
The interchangeability status would be of significant interest for corporate and firm attorneys who advise clients in the pharmaceutical industry. The status means that, the pharmacists can substitute the original brand-name product, LUCENTIS, with BYOOVIZ without requiring any approval from the prescribing healthcare provider. Consequently, this could have a wide-ranging impact on market dynamics and patent litigation in the pharmaceutical sector.
The legal implications of interchangeable biosimilars require profound understanding of federal and state regulations. Moreover, lawsuits relating to interchangeable biosimilars are likely to be complex and high-stakes, and attorneys from diverse specialties, such as intellectual property, health care, and corporate law, might need to work together to defend their clients’ interests.
Keeping in mind the global reach of many pharmaceutical firms, legal teams would also need to consider regulations and legal frameworks in other countries where their clients operate.
With this historic decision by the FDA, BYOOVIZ® is leading the way for future biosimilars seeking interchangeable status. Therefore, it would be prudent in the upcoming months, for legal professionals to closely monitor this field, not only to stay abreast with any legal challenges and regulatory changes that might arise, but also to shape their own legal strategies.
For more detailed information on this decision by the FDA, you can review the original article on JD Supra.